🟢 INCY is trading 6% up today following clinical updates and a favorable Medicaid settlement

INCY is trading 6% up at $113.97 following a series of positive clinical and regulatory developments alongside a broader sector rebound.

• Key catalysts include pivotal lymphoma data, positive rare-disease results, and a favorable Medicaid settlement for its Opzelura treatment.
• The stock continues to build on momentum from the prior week, supported by early-stage findings in myeloproliferative neoplasms and improved sentiment across the biotech industry.